JUPITER, Fla., June 30, 2011 /PRNewswire/ -- Stem Cell Assurance, Inc. (SCLZ.PK) ("SCA") today announced the launch of a platform technology that involves the use of brown fat for cell-based therapeutic/cosmetic purposes. Through its brown fat program, SCA intends to develop treatments for weight loss and metabolic disorders. SCA will initially focus on cellular therapies for obesity and its adverse effect on health, which could lead to several serious and sometimes fatal diseases such as diabetes, ischemic heart disease, stroke, hypertension and kidney failure.
Brown fat is one of two types of known adipose (fat) tissue found in the human body and is involved in homeostasis by creating metabolic tissue capable of producing heat. Recent studies have demonstrated that brown fat is present in the adult human body and may be correlated with the maintenance and regulation of metabolism, thus potentially being involved in caloric regulation.
SCA intends to use autologous cells (i.e., stem cells isolated from individual patients) that may be differentiated into progenitor or fully differentiated brown adipocytes, or a related cell type, that can be used therapeutically or cosmetically in patients. As the brown fat cellular program advances, SCA will seek to determine whether data derived from the program can be useful in developing a small molecule drug therapy.
Mark Weinreb, SCA's Chairman and Chief Executive Officer, said, "I am pleased to announce our first 'flagship' cellular platform technology that has the potential to treat the onset of many serious diseases, as well as provide a novel opportunity to explore a natural 'biological' weight loss program. This represents a significant step for SCA to become a leader in a field of stem cell science that has not been saturated with exploration and is directed to a large commercial market."
About Stem Cell Assurance, Inc.